Halberd (Halberd) Cash Flow for Lease Financing : $ Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Cash Flow for Lease Financing?

Halberd's Cash Flow for Lease Financing for the six months ended in Jul. 2023 was $0.00 Mil. Halberd does not have enough years/quarters to calculate the Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jul. 2023.

Compared with last quarter ($0.00 Mil in Jul. 2022 ), Halberd's Cash Flow for Lease Financing remained the same in Jul. 2023 ($0.00 Mil).

Halberd Cash Flow for Lease Financing Historical Data

The historical data trend for Halberd's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Cash Flow for Lease Financing Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Cash Flow for Lease Financing

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Cash Flow for Lease Financing	-	-	-

Halberd Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Halberd Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Halberd's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236